Related Experiment Video
Updated: Aug 25, 2025
10:46
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
3.8K
Small molecule inhibitors targeting the cancers
Gui-Hong Liu1, Tao Chen2, Xin Zhang1
1Department of Biotherapy State Key Laboratory of Biotherapy Cancer Center, West China Hospital Sichuan University Chengdu China.
Medcomm
|October 18, 2022
Summary
Small molecule inhibitors offer targeted cancer therapy advantages but face challenges like resistance and low response rates. This review analyzes approved drugs and candidates to guide future development and overcome obstacles.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Targeted therapy, particularly small molecule inhibitors, shows promise over traditional cancer treatments due to improved selectivity, efficacy, and tolerability.
- Small molecule inhibitors are crucial in oncology, with 88 FDA-approved agents, offering advantages like broad target engagement and central nervous system penetration.
- Despite progress, challenges persist, including low response rates, limited duration of response, toxicity, biomarker identification, and acquired resistance.
Purpose of the Study:
- To comprehensively review approved small molecule inhibitors and clinical candidates for cancer treatment.
- To organize agents by signaling pathways and inhibitor classification to provide a structured overview.
- To offer insights into overcoming resistance mechanisms and explore combination therapies for enhanced efficacy.
Main Methods:
- Systematic review of FDA-approved small molecule inhibitors for cancer.
- Analysis of pivotal drug candidates currently in clinical trials.
- Categorization of agents based on targeted signaling pathways and inhibitor class.
- Discussion of developmental challenges, resistance mechanisms, and combination strategies.
Main Results:
- Identified 88 FDA-approved small molecule inhibitors for cancer treatment.
- Detailed review of agents targeting various signaling pathways and classified by inhibitor type.
- Exploration of strategies to address common obstacles such as resistance and low response rates.
- Consideration of combination therapies involving small molecule inhibitors.
Conclusions:
- Small molecule inhibitors represent a significant advancement in cancer therapy, but development requires addressing key challenges.
- Strategies for overcoming resistance and optimizing combination therapies are crucial for improving patient outcomes.
- This review provides a valuable resource for researchers and developers in advancing small molecule inhibitor-based cancer treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:26Targets for Drug Action: Overview
7.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.2K
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
02:30siRNA - Small Interfering RNAs
16.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K